Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews · Haematology

No studies found 1 · 25%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 75%Moderate 0 · 0%High 0 · 0%

Admission to hospital or death · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Bamlanivimab/etesevimab may leads to lower admission to hospital or death compared with placebo (low certainty).

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
RR 0.3 [0.16, 0.59]
1 study · 1035 participants
Low

Admission to hospital or death · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Admission to hospital or death · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Sotrovimab may leads to lower admission to hospital or death by day 30 compared with placebo (low certainty).

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
RR 0.14 [0.04, 0.48]
1 study · 583 participants
Low

Admission to hospital or death · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Regdanvimab showed no clear difference in admission to hospital or death by day 30Â compared with placebo (low certainty).

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
RR 0.45 [0.14, 1.42]
1 study · 204 participants
Low